# US 2023/0058733 A1 · Oga inhibitor compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058733 A1
- Document ID: US20230058733A1
- Status: Published application
- Kind: A1
- Application number: 17/757,637
- Filed: 2020-12-18
- Published: 2023-02-23
- Earliest claimed: 2019-12-18
- Assignees: Janssen Pharmaceutica NV
- Applicants: Janssen Pharmaceutica NV
- Inventors: José Manuel BARTOLOMÉ-NEBREDA; Petrus Jacobus Johannes Antonius BUIJNSTERS; Joseph Elisabeth LEENAERTS; Carolina MARTINEZ LAMENCA; Daniel OEHLRICH; Andrés Avelino TRABANCO-SUÁREZ; Yves Emiel M VAN ROOSBROECK; Adriana Ingrid VELTER
- Web page: https://patentgrep.com/patent/US20230058733A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 25/00: Drugs for disorders of the nervous system
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

## Claims

### Claim 1

A compound of Formula (I)
or a tautomer or a stereoisomeric form thereof, wherein
R1 is selected from the group consisting of —C1-4alkyl-C(═O)NRxRy; C1-6alkyl optionally substituted with one or more substituents, each independently selected from the group consisting of halo, —CN, —OC1-4alkyl, OH, oxazolyl, C3-6cycloalkyl optionally substituted with one or more independently selected halo substituents;
with the proviso that a —OC1-4alkyl or —OH substituent, when present, is at least two carbon atoms away from the nitrogen atom of the bicyclic core;
wherein Rx and Ry are each independently selected from the group consisting of hydrogen, C1-4 alkyl, monohaloC1-4alkyl, polyhaloC1-4alkyl, and C3-6cycloalkyl; or Rx and Ry together with the nitrogen atom to which they are attached form a heterocyclyl ring selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl;
R2 and R4 when present, are each independently selected from the group consisting of hydrogen, halo, C1-4alkyl and C3-6cycloalkyl; and
R3 is a 5- or 6-membered monocyclic aryl or heteroaryl radical selected from the group consisting of pyrazolyl, phenyl and pyridyl; each of which is substituted with one or more substituents, each independently selected from the group consisting of halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, polyhaloC1-4alkyloxy, —(C═O)C1-4alkyl, and Het; and wherein at least one substituent is positioned at the carbon atom ortho- to the NH linker binding R4 to the bicyclic core; wherein
Het is selected from the group consisting of pyrazolyl, phenyl, pyridyl optionally substituted with one or more substituents, each independently selected from the group consisting of halo, C1-4alkyl, —CN, C1-4alkyloxy;
or a pharmaceutically acceptable addition salt or a solvate thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein
R3 is selected from the group consisting of (a) and (b):
wherein R1a, R2a, R1b and R2b are each independently selected from the group consisting of hydrogen, halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, polyhaloC1-4alkyloxy, —(C═O)C1-4alkyl, and Het; with the proviso that at least one of R1a or R2a, and at least one of R1b or R2b is not hydrogen;
Z1 and Z2 are each independently selected from N, CH or CR3b, with the proviso that at least one of Z1 or Z2 is N;
R3a and R3b when present, are each independently selected from the group consisting of halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, polyhaloC1-4alkyloxy, —(C═O)C1-4alkyl, and Het; wherein
n represents 0, 1 or 2; and
Het is selected from the group consisting of pyrazolyl, phenyl, pyridyl optionally substituted with one or more substituents, each independently selected from the group consisting of halo, C1-4alkyl, —CN, C1-4alkyloxy.

### Claim 3 (depends on 2)

The compound according to claim 2, wherein
R3 is group (a) or (b):
wherein R1a, R2a, R1b and R2b are each independently selected from the group consisting of halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, and polyhaloC1-4alkyloxy;
Z1 and Z2 are each independently selected from N, CH or CR3b, with the proviso that at least one of Z1 or Z2 is N; and
R3a and R3b when present, are each independently selected from the group consisting of halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, and polyhaloC1-4alkyloxy; wherein
n represents 0, 1 or 2.

### Claim 4 (depends on 3)

The compound according to claim 3,
wherein R3 is group (a) or (b):
wherein R1a, R2a, R1b and R2b are each independently selected from the group consisting of halo, C1-4alkyl, —CN, polyhaloC1-4alkyl, C1-4alkyloxy, and polyhaloC1-4alkyloxy;
Z1 and Z2 are each independently selected from N, CH or CR3b, with the proviso that at least one of Z1 or Z2 is N; and
R3a and R3b when present, are each independently selected from the group consisting of halo, C1-4alkyl, —CN, polyhaloC1-4alkyl, C1-4alkyloxy, and polyhaloC1-4alkyloxy; wherein
n represents 0 or 1.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising a prophylactically or a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 6 (depends on 1, 5)

A process for preparing the pharmaceutical composition according to claim 5, comprising mixing a pharmaceutically acceptable carrier with a prophylactically or a therapeutically effective amount of a compound according to claim 1.

### Claim 7

(canceled)

### Claim 8

A method of treating or preventing a tauopathy, or an alpha synucleinopathy, comprising:
administering to a subject in need thereof a prophylactically or therapeutically effective amount of a compound of Formula (I)
or a tautomer or a stereoisomeric form thereof, wherein
R1 is selected from the group consisting of —C1-4alkyl-C(═O)NRxRy C1-6alkyl optionally substituted with one or more substituents, each independently selected from the group consisting of halo, —CN, —OC1-4alkyl, OH, oxazolyl, C3-6cycloalkyl optionally substituted with one or more independently selected halo substituents;
with the proviso that a —OC1-4alkyl or —OH substituent, when present, is at least two carbon atoms away from the nitrogen atom of the bicyclic core;
wherein Rx and Ry are each independently selected from the group consisting of hydrogen, C1-4 alkyl, monohaloC1-4alkyl, polyhaloC1-4alkyl, and C3-6cycloalkyl; or Rx and Ry together with the nitrogen atom to which they are attached form a heterocyclyl ring selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl;
R2 and R4 when present, are each independently selected from the group consisting of hydrogen, halo, C1-4alkyl and C3-6cycloalkyl; and
R3 is a 5- or 6-membered monocyclic aryl or heteroaryl radical selected from the group consisting of pyrazolyl, phenyl and pyridyl; each of which is substituted with one or more substituents, each independently selected from the group consisting of halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, polyhaloC1-4alkyloxy, —(C═O)C1-4alkyl, and Het; and wherein at least one substituent is positioned at the carbon atom ortho- to the NH linker binding R4 to the bicyclic core; wherein
Het is selected from the group consisting of pyrazolyl, phenyl, pyridyl optionally substituted with one or more substituents, each independently selected from the group consisting of halo, C1-4alkyl, —CN, C1-4alkyloxy;
or a pharmaceutically acceptable addition salt or a solvate thereof.

### Claim 9 (depends on 8)

The method according to claim 8,
wherein the tauopathy is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, parkinsonism-dementia complex, argyrophilic grain disease, chronic traumatic encephalopathy, corticobasal degeneration, diffuse neurofibrillary tangles with calcification, Down's syndrome, Familial British dementia, Familial Danish dementia, Frontotemporal dementia and parkinsonism linked to chromosome 17, Frontotemporal lobar degeneration, Gerstmann-Straussler-Scheinker disease, Parkinson's disease, Guadeloupean parkinsonism, myotonic dystrophy, neurodegeneration with brain iron accumulation, Niemann-Pick disease, type C non-Guamanian motor neuron disease with neurofibrillary tangles, Pick's disease, postencephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, progressive supranuclear palsy, SLC9A6-related mental retardation, subacute sclerosing panencephalitis, tangle-only dementia, and white matter tauopathy with globular glial inclusions, and
wherein the alpha synucleinopathy is selected from the group consisting of Parkinson's disease, dementia due to Parkinson's, neurocognitive disorder due to Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and alpha synucleinopathy caused by Gaucher's disease.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the compound controls or reduces risk of preclinical Alzheimer's disease, prodromal Alzheimer's disease, or tau-related neurodegeneration as observed in different forms of tauopathies.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the compound controls or reduces risk of prodromal Parkinson's disease.

### Claim 12

(canceled)

### Claim 13

A method for inhibiting O-GlcNAc hydrolase, comprising:
administering to a subject in need thereof, a prophylactically or a therapeutically effective amount of a compound of Formula (I)
or a tautomer or a stereoisomeric form thereof, wherein
R1 is selected from the group consisting of —C1-4alkyl-C(═O)NRxRy; C1-6alkyl optionally substituted with one or more substituents, each independently selected from the group consisting of halo, —CN, —OC1-4alkyl, OH, oxazolyl, C3-6cycloalkyl optionally substituted with one or more independently selected halo substituents;
with the proviso that a —OC1-4alkyl or —OH substituent, when present, is at least two carbon atoms away from the nitrogen atom of the bicyclic core;
wherein Rx and Ry are each independently selected from the group consisting of hydrogen, C1-4 alkyl, monohaloC1-4alkyl, polyhaloC1-4alkyl, and C3-6cycloalkyl; or Rx and Ry together with the nitrogen atom to which they are attached form a heterocyclyl ring selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl;
R2 and R4 when present, are each independently selected from the group consisting of hydrogen, halo, C1-4alkyl and C3-6cycloalkyl; and
R3 is a 5- or 6-membered monocyclic aryl or heteroaryl radical selected from the group consisting of pyrazolyl, phenyl and pyridyl; each of which is substituted with one or more substituents, each independently selected from the group consisting of halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, polyhaloC1-4alkyloxy, —(C═O)C1-4alkyl, and Het; and wherein at least one substituent is positioned at the carbon atom ortho- to the NH linker binding R4 to the bicyclic core; wherein
Het is selected from the group consisting of pyrazolyl, phenyl, pyridyl optionally substituted with one or more substituents, each independently selected from the group consisting of halo, C1-4alkyl, —CN, C1-4alkyloxy;
or a pharmaceutically acceptable addition salt or a solvate thereof.

### Claim 14 (depends on 8)

The method according to claim 8, wherein
R3 is selected from the group consisting of (a) and (b):
wherein R1a, R2a, R1b and R2b are each independently selected from the group consisting of hydrogen, halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, polyhaloC1-4alkyloxy, —(C═O)C1-4alkyl, and Het; with the proviso that at least one of R1a or R2a, and at least one of R1b or R2b is not hydrogen;
Z1 and Z2 are each independently selected from N, CH or CR3b, with the proviso that at least one of Z1 or Z2 is N;
R3a and R3b when present, are each independently selected from the group consisting of halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, polyhaloC1-4alkyloxy, —(C═O)C1-4alkyl, and Het; wherein
n represents 0, 1 or 2; and
Het is selected from the group consisting of pyrazolyl, phenyl, pyridyl optionally substituted with one or more substituents, each independently selected from the group consisting of halo, C1-4alkyl, —CN, C1-4alkyloxy.

### Claim 15 (depends on 14)

The method according to claim 14, wherein
R3 is group (a) or (b):
wherein R1a, R2a, R1b and R2b are each independently selected from the group consisting of halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, and polyhaloC1-4alkyloxy;
Z1 and Z2 are each independently selected from N, CH or CR3b, with the proviso that at least one of Z1 or Z2 is N; and
R3a and R3b when present, are each independently selected from the group consisting of halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, and polyhaloC1-4alkyloxy; wherein
n represents 0, 1 or 2.

### Claim 16 (depends on 15)

The method according to claim 15, wherein R3 is group (a) or (b):
wherein R1a, R2a, R1b and R2b are each independently selected from the group consisting of halo, C1-4alkyl, —CN, polyhaloC1-4alkyl, C1-4alkyloxy, and polyhaloC1-4alkyloxy;
Z1 and Z2 are each independently selected from N, CH or CR3b, with the proviso that at least one of Z1 or Z2 is N; and
R3a and R3b when present, are each independently selected from the group consisting of halo, C1-4alkyl, —CN, polyhaloC1-4alkyl, C1-4alkyloxy, and polyhaloC1-4alkyloxy; wherein
n represents 0 or 1.

### Claim 17 (depends on 13)

The method according to claim 13, wherein
R3 is selected from the group consisting of (a) and (b):
wherein R1a, R2a, R1b and R2b are each independently selected from the group consisting of hydrogen, halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, polyhaloC1-4alkyloxy, —(C═O)C1-4alkyl, and Het; with the proviso that at least one of R1a or R2a, and at least one of R1b or R2b is not hydrogen;
Z1 and Z2 are each independently selected from N, CH or CR3b, with the proviso that at least one of Z1 or Z2 is N;
R3a and R3b when present, are each independently selected from the group consisting of halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, polyhaloC1-4alkyloxy, —(C═O)C1-4alkyl, and Het; wherein
n represents 0, 1 or 2; and
Het is selected from the group consisting of pyrazolyl, phenyl, pyridyl optionally substituted with one or more substituents, each independently selected from the group consisting of halo, C1-4alkyl, —CN, C1-4alkyloxy.

### Claim 18 (depends on 17)

The method according to claim 17, wherein
R3 is group (a) or (b):
wherein R1a, R2a, R1b and R2b are each independently selected from the group consisting of halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, and polyhaloC1-4alkyloxy;
Z1 and Z2 are each independently selected from N, CH or CR3b, with the proviso that at least one of Z1 or Z2 is N; and
R3a and R3b when present, are each independently selected from the group consisting of halo, C1-4alkyl, —CN, monohaloC1-4alkyl, polyhaloC1-4alkyl, C1-4alkyloxy, monohaloC1-4alkyloxy, and polyhaloC1-4alkyloxy; wherein
n represents 0, 1 or 2.

### Claim 19 (depends on 18)

The method according to claim 18, wherein R3 is group (a) or (b):
wherein R1a, R2a, R1b and R2b are each independently selected from the group consisting of halo, C1-4alkyl, —CN, polyhaloC1-4alkyl, C1-4alkyloxy, and polyhaloC1-4alkyloxy;
Z1 and Z2 are each independently selected from N, CH or CR3b, with the proviso that at least one of Z1 or Z2 is N; and
R3a and R3b when present, are each independently selected from the group consisting of halo, C1-4alkyl, —CN, polyhaloC1-4alkyl, C1-4alkyloxy, and polyhaloC1-4alkyloxy; wherein
n represents 0 or 1.

### Claim 20 (depends on 9)

The method according to claim 9, wherein the Frontotemporal dementia and parkinsonism linked to chromosome 17 is caused by MAPT mutations.

### Claim 21 (depends on 9)

The method according to claim 9, wherein the Frontotemporal lobar degeneration is caused by C9ORF72 mutations.
